• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

    1/8/25 8:00:00 AM ET
    $AGIO
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGIO alert in real time by email

    Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals (NASDAQ:AGIO), and previously held strategic product and portfolio roles at Biogen (NASDAQ:BIIB). In her role at Cardurion, she will be responsible for leading corporate development, business development, portfolio strategy and new product planning to help Cardurion maximize opportunities for its growing portfolio of cardiovascular drug candidates.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108574324/en/

    Cardurion CBO Charlotte Newman (Photo: Business Wire)

    Cardurion CBO Charlotte Newman (Photo: Business Wire)

    "We are delighted to welcome Charlie to the Cardurion leadership team at this pivotal time in our growth. She brings exceptional expertise and judgment in corporate strategy and development, business development and portfolio strategy that will contribute to realizing the many opportunities offered by our clinical pipeline of potential first-in-class therapies for cardiovascular diseases in areas of high unmet need," said Peter Lawrence, Chief Executive Officer of Cardurion. "Charlie's experience and track record of assembling and advancing portfolios of important medicines and leading major business transactions will help to enable our goal of building a world-class company and bringing groundbreaking therapeutics to patients with cardiovascular diseases."

    "I am excited to join the outstanding team at Cardurion at this important time in the company's evolution," said Ms. Newman. "The progress made so far – building and advancing a compelling pipeline with meaningful clinical momentum – speaks volumes about the depth of talent and vision within this team. I look forward to leveraging my experience to help Cardurion accelerate and achieve its broader aspirations and deliver on the promise to dramatically change the course of cardiovascular disease for patients."

    Ms. Newman became Chief Business Officer of Agios Pharmaceuticals in January 2022, after previously serving as senior vice president of portfolio leadership and joining the company as vice president of its rare disease program in 2018. As CBO, she was responsible for the strategy and execution of Agios' portfolio as it evolved to focus on potential first and best-in-class therapeutics to address diseases of high unmet need in non-malignant hematology. Leading business development, she was instrumental in balancing portfolio investments, expanding the company's portfolio and identifying paths to value inflection. Previously, Ms. Newman served at Biogen as vice president and asset executive, Alzheimer's disease, and vice president, R&D portfolio leadership. Earlier in her career, she worked in roles in clinical development and operations at Biogen, Provensis Ltd, a BTG International Group company, and G.D. Searle and Company, a division of Monsanto. Ms. Newman earned a Bachelor's degree in Animal Physiology with Biochemistry from the University of Leicester in the UK.

    About Cardurion Pharmaceuticals

    Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Cardurion was founded by physician-scientists with world-class expertise in cardiovascular signaling pathways, and a shared passion to find and develop a pipeline of novel treatment options to improve the lives of patients. Cardurion has two groundbreaking clinical programs in development, a potential first-in-class phosphodiesterase-9 (PDE9) inhibitor for both types of chronic heart failure and the first-ever clinical-stage Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor for rare and common cardiovascular diseases.

    Cardurion Pharmaceuticals is headquartered in Burlington, Massachusetts, with discovery sciences and research facilities in Shonan, Japan. For more information, please visit the company's website at https://cardurion.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250108574324/en/

    Media Contact:

    Kathryn Morris

    The Yates Network LLC

    914-204-6412

    [email protected]

    Get the next $AGIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIO
    $BIIB

    CompanyDatePrice TargetRatingAnalyst
    Biogen Inc.
    $BIIB
    9/25/2025$190.00Buy
    Jefferies
    Biogen Inc.
    $BIIB
    7/21/2025$142.00Hold
    Truist
    Biogen Inc.
    $BIIB
    4/28/2025$118.00Buy → Hold
    HSBC Securities
    Biogen Inc.
    $BIIB
    4/4/2025Buy → Hold
    Argus
    Agios Pharmaceuticals Inc.
    $AGIO
    2/24/2025$58.00Buy
    H.C. Wainwright
    Biogen Inc.
    $BIIB
    2/11/2025$160.00Mkt Perform
    Bernstein
    Biogen Inc.
    $BIIB
    1/2/2025$315.00 → $138.00Overweight → Neutral
    Piper Sandler
    Biogen Inc.
    $BIIB
    12/20/2024$230.00 → $164.00Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $AGIO
    $BIIB
    SEC Filings

    View All

    SEC Form 144 filed by Agios Pharmaceuticals Inc.

    144 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    10/8/25 4:01:36 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

    8/4/25 1:53:22 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Agios Pharmaceuticals Inc.

    10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

    7/31/25 10:29:01 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    $BIIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately. The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape. Mant

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

    – An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improvements in overall clinical status at 3 years in the open-label extension studies reported by clinicians and caregivers in 95% of patients treated with zorevunersen – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced the presentation of longer-term follow-up analyses from the ongoing open-label extension

    10/9/25 4:30:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AGIO
    $BIIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scadden David exercised 200 shares at a strike of $18.09 and sold $8,200 worth of shares (200 units at $41.00) (SEC Form 4)

    4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

    10/10/25 4:18:07 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Godbout Sean converted options into 26 shares and covered exercise/tax liability with 8 shares, increasing direct ownership by 4% to 495 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    10/6/25 1:00:24 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Scadden David exercised 200 shares at a strike of $18.09 and sold $8,000 worth of shares (200 units at $40.00) (SEC Form 4)

    4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

    10/2/25 4:03:54 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    $BIIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dorsa Caroline bought $151,559 worth of shares (1,235 units at $122.72), increasing direct ownership by 5% to 27,842 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    5/5/25 4:17:10 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/20/24 9:13:26 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIO
    $BIIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling

    3/25/24 4:41:37 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIO
    $BIIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Biogen with a new price target

    Jefferies initiated coverage of Biogen with a rating of Buy and set a new price target of $190.00

    9/25/25 8:28:11 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist resumed coverage on Biogen with a new price target

    Truist resumed coverage of Biogen with a rating of Hold and set a new price target of $142.00

    7/21/25 8:31:03 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Biogen downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Biogen from Buy to Hold and set a new price target of $118.00

    4/28/25 8:32:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGIO
    $BIIB
    Leadership Updates

    Live Leadership Updates

    View All

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately. The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape. Mant

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Agios Appoints Dr. Jay Backstrom to Board of Directors

    CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, effective immediately. Dr. Backstrom is an accomplished healthcare executive with a proven track record of advancing clinical programs across a range of therapeutic areas, including rare diseases, to regulatory approval. "We are thrilled to welcome Jay to the Agios Board of Directors," said Brian Goff, Chief Executive Officer, Agios. "His deep scientific insight, extensive regulatory expertise, and s

    7/8/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    $BIIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

    SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    11/14/24 3:44:53 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/12/24 1:24:28 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

    SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    11/8/24 2:40:47 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    $BIIB
    Financials

    Live finance-specific insights

    View All

    Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

    $12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securitiesPYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September 7, 2025Topline results from RISE UP Phase 3 trial of mitapivat in sickle cell disease on track by year-end with potential U.S. commercial launch in 2026Dosed first patient in the tebapivat Phase 2 sickle cell disease trial and received IND clearance for AG-236 CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicine

    7/31/25 6:30:23 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

    CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 31, 2025, at 8:00 a.m. ET to report its second quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company's website approximately two hours after the event. About AgiosAgios is the pioneering leader in PK a

    7/14/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

    Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

    6/25/25 7:30:37 AM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations